The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumRecap - Investors descend en masse on San Francisco next week for the annual JP Morgan healthcare conference, a major event for the sector that historically generates … Continue Reading
Read nowResearch - Conatus Pharmaceuticals (CNAT) will release the combined results from 3 phase 1 and 2 studies on Thursday after the bell. CNAT is up 60% from our suggestion to get long the stock this Fall at $6.00.
PremiumInsights - Arena Pharmaceuticals (ARNA) was up as much as 40% on Wednesday with the release of phase I data for APD334.
Read nowResearch - By Zack Fink and guest contributor Dan Marks Bluebird bio (BLUE) will release data from the first Sickle Cell Disease patient treated with its LentiGlobin gene therapy … Continue Reading
Read nowInsights - Shortly before the bell on Monday morning, Kite Pharma (KITE) announced an immunotherapy collaboration and licensing agreement with one of biotech’s juggernauts, Amgen (AMGN), to advance … Continue Reading
Read nowResearch - Solithromycin proves non-inferior to moxifloxacin in phase 3 SOLITAIRE-ORAL trial, meets endpoints endorsed by both U.S. and E.U. regulators. Enrollment update for SOLITAIRE-IV is expected in … Continue Reading
PremiumInsights - 2014 was a stellar year in biotech, for investors as well as patients. Here’s to an even better 2015. Happy new year! At PropThink, our goal has always … Continue Reading
Read now
